Training Example: Loyal Animal Health, Inc – Review the Data, Give Your Score & Compare to the Real AI Evaluation

Skip to main contentOne step closer to a longevity drug: LOY-002 hits key FDA milestone. Read more →
[H1] We're developing the first longevity drugs for dogs.
WatchStay connectedBuckAge 9
[H2] Our approach
Aging is the most significant modifiable risk factor for many degenerative and chronic diseases in adult dogs. Targeting the ways dogs age and decline over time may be one of the most effective and practical ways to increase their healthy lifespan.At Loyal, our approach is to help dogs live longer and stay healthier as they age by developing drugs that target the underlying processes that lead to age-associated disease and disability.3drug programs in development70veterinary clinics in STAY clinical trial1,317dogs enrolled in STAY clinical trial
[IMG: Illustration representing our approach to developing longevity drugs for dogs]
[IMG: Chase, age 12]
ChaseAge 12
[IMG: Abby, a Beagle mix, age 13]
AbbyAge 13LOY-002Meet our lead drug for
[H2] Senior dogs
LOY-002 targets metabolic dysfunction, a core driver of the diseases many senior dogs experience as they age. By addressing the root cause, LOY-002 aims to extend lifespan and maintain quality of life for longer.Target populationDogs age 10+, 14+ lbHow it worksImproving age-associated metabolic dysfunction through a once-daily pillFDA approval progress2/3 major requirements completed. FDA approval not guaranteed.RXE: preliminary efficacy dataAcceptedTAS: safety studiesAcceptedCMC: manufacturingIn progress
[IMG: Abby, a Beagle mix, age 13]
[IMG: Abby, a Beagle mix, age 13]
AbbyAge 13We're developing a portfolio of aging therapeutics.Explore all products
[IMG: Dog owner with a golden retriever]
[H2] Dog owners
Is Loyal developing drugs for my dog?Science-backed care for your aging dogBe the first to know when Loyal drugs are available
[IMG: Veterinarian with a golden retriever]
[H2] Veterinarians
Earn free CE credit in canine agingLearn about our clinical trialsResources for senior dog care
[H2] Good news for senior dogs
We've hit a major milestone. LOY-002 just completed the second of three major requirements for FDA conditional approval. It's the clearest signal yet that a longevity drug for dogs could be available soon.What this means for senior dogs
[IMG: Harper, age 11]
HarperAge 11Race-approved CE courses
[H2] The Loyal Learning Hub is the definitive resource for canine aging. Our free library of RACE-approved courses helps veterinary teams easily earn CE and deliver better care to senior dogs.
Start learning
[IMG: The Loyal Learning Hub course portal]
[H2] Loyal in the news
[IMG: Longer Leash On Life: Inside The Dog Longevity Startup article thumbnail]
Longer Leash On Life: Inside The Dog Longevity Startup
[IMG: Studying dogs may reveal path to longer, healthier life for dogs, humans article thumbnail]
Studying dogs may reveal path to longer, healthier life for dogs, humans
[IMG: New pill could help dogs live longer article thumbnail]
New pill could help dogs live longer
[IMG: Antiaging pill for dogs clears key FDA hurdle article thumbnail]
Antiaging pill for dogs clears key FDA hurdle
[IMG: Could a Drug Give Your Pet More Dog Years? article thumbnail]
Could a Drug Give Your Pet More Dog Years?
[IMG: The Clues to Longer Life That Are Coming From Dogs article thumbnail]
The Clues to Longer Life That Are Coming From Dogs

Skip to main contentOne step closer to a longevity drug: LOY-002 hits key FDA milestone. Read more →New longevity drugs for your canine patientsAdvance your practice with longevity science through RACE-approved CE courses.View our CE content
[IMG: Chance, age 8]
ChanceAge 8Dr. Casey TalbotVeterinarianExtending healthy lifespanAging is the most significant modifiable risk factor for most degenerative and chronic diseases in adult dogs. Targeting the ways dogs age and decline over time may be one of the most effective and practical ways for veterinarians to increase the healthy lifespan of their canine patients.At Loyal, our approach is to help dogs live longer and stay healthier as they age by targeting the underlying processes that lead to age-associated disease and disability. Our drugs aim to extend lifespan and quality of life by reducing incidence or severity of age-related diseases.
[IMG: Aging graph]
A guide to our drugs in developmentWe're developing the first longevity drugs for dogs. With three products currently in our pipeline, we're making progress toward approval from the FDA's Center for Veterinary Medicine.*FDA approval not guaranteedDownload guideLOY-002For senior dogsLOY-002 is intended for dogs aged 10 or older and weighing at least 14 lb. It aims to extend healthy lifespan by targeting age-associated metabolic dysfunction.As dogs age their metabolic health declines, leading to disease and reduced lifespan. Our aim with LOY-002 is to preserve metabolic health, which we believe will delay the onset of age-associated disease and help maintain better function and quality of life.We’ve launched a double-blinded, placebo-controlled efficacy study recruiting 1,300 senior dogs in partnership with 70 veterinary clinics across the country. Learn more about the STAY study.LOY-001LOY-003For large dogsLOY-001 and LOY-003 are intended for large and giant dogs and target the over-expression of IGF-1, a hormone that we believe is associated with large dogs’ shorter lifespan relative to small dogs. Large body size in dogs is correlated with shortened lifespan, so the larger a breed is, the shorter the average longevity of dogs in that breed. We believe that sustained higher levels of Growth Hormone and IGF-1 in larger dogs are partly responsible for shorter lifespan and the earlier development of age-associated disease and disability. Our aim for LOY-001 and LOY-003 is to address this overexpression in adult dogs with the aim of reducing age-associated diseases and extending healthy lifespan. LOY-001 is a prescription long-acting injection for dogs 7 years or older and weighing at least 40 lb, while LOY-003 is a prescription daily pill for dogs 5 years or older and weighing at least 60 lb. Learn more about these products for large dogs.
[IMG: Dr Ellen Ratcliff with Dr Casey Talbot]
Dr. Ellen RatcliffVP of Clinical and Veterinary Medicine at LoyalDr. Casey TalbotVeterinarian
[IMG: Dr. Jessa Kocher, Veterinarian]
Dr. Jessa KocherVeterinarianLOY-002 milestonesOur dog longevity drugs LOY-001, LOY-002, and LOY-003 are all being developed under the FDA Center for Veterinary Medicine’s expanded conditional approval (XCA) pathway. XCA is a new regulatory pathway that allows certain animal drugs to be conditionally approved based on: Full safety dataFull manufacturing dataReasonable expectation of effectivenessLearn more about XCAHealthspan StudyIn this study, we recruited dogs from across the United States from 2 to 18 years old, ranging from less than 15 to over 120 pounds. We analyzed 451 of these dogs to test how well the veterinary-assessed Canine Frailty Index and the owner-assessed Health-Related Quality of Life tool measured the effects of frailty and quality of life in both young and old dogs. Other endpoints included a thorough veterinary examination and blood marker measurements. This study has been published in a peer-reviewed journal.Proof-of-conceptLaboratory studies were used to identify the optimal dose of LOY-002 for future studies. Then studies were run to assess the ability of LOY-002 to impact age-associated biomarkers and confirm the dose for use in pilot studies and the pivotal effectiveness study. These studies provided the information that supports our application for Reasonable Expectation of Effectiveness (RXE) for LOY-002.Pilot studiesA pilot study — as the name suggests — is a smaller-scale study intended to test both the drug and the design and operational structure of the research. This was especially important in preparation for our STAY study, which is likely one of the largest veterinary clinical trials ever run!RXE technical section completeOur senior dog drug LOY-002 received a Reasonable Expectation of Effectiveness (RXE) technical section complete, which means the FDA believes that LOY-002 is likely to be effective for dog lifespan extension in the real world.TAS technical section completeThe Target Animal Safety (TAS) technical section is an FDA submission that will present all safety information on the drug, and the FDA determines whether the drug is safe for the proposed use.Safety studiesThe safety of LOY-002 in dogs has been evaluated in a number of laboratory studies and a pilot clinical study. Over 400 dogs have received this drug in laboratory studies, including longitudinal studies of up to a year. In a 3-month pilot clinical study performed at general practice veterinary clinics, 48 dogs were treated with LOY-002 and showed no clinically significant adverse effects. We’re also running a 6-month study to assess safety of LOY-002 tablets at up to five times the expected prescription dose.Companion dog clinical studyIn progressThe STAY study is our pivotal efficacy study designed to demonstrate lifespan extension in senior dogs treated with LOY-002, a daily pill that aims to extend healthy lifespan in senior dogs of all but the smallest sizes. After this study’s conclusion, the data will be submitted to the FDA to support full approval.CMC technical section completeIn progressThe Chemistry Manufacturing and Controls (CMC) technical section is an FDA submission that will demonstrate that LOY-002 can be manufactured consistently and safely, meeting all quality standards.Conditional FDA approvalIn progressThe FDA Center for Veterinary Medicine's expanded conditional approval process allows companies to bring certain products to patients while conducting longer effectiveness studies, specifically when the product meets an important unmet need. This helps us get treatment as early as possible to older dogs who need it most. To receive conditional approval, the product must meet the same rigorous safety and manufacturing standards as drugs that are fully approved.Available in marketIn progressIf the FDA CVM grants conditional approval for LOY-002, veterinarians will be able to prescribe the drug to qualified dogs while the STAY study continues to gather the lifespan data required for full approval.
[IMG: Dr. Tanner, veterinarian with dog Archer, age 5]
ArcherAge 5Dr. Tanner LeonVeterinarianResources for veterinary professionalsOur Continuing Education content has movedWe've upgraded our CE platform with new courses, progress tracking, and certificates.Access CE PortalDownloadable resourcesProduct brief for veterinary professionalsDownloadResources for dog ownersDownloadCanine aging resourcesDownloadCanine Frailty IndexDownloadPublicationsSummaries of our scientific publicationsFrom the start, Loyal has pursued publication in peer-reviewed journals. By publishing our research, we ensure transparency, credibility, and accessibility, enabling others to build upon our work and drive progress in their respective fields. No matter whether our results are positive or negative, we’re committed to sharing our findings.Read summaries
[IMG: GeroScience]
December 17, 2025Multi-omic analysis of canine aging uncovers conserved aging pathwaysKoch, Z., Graves, J.L., Annan, S. et al. Multi-omic analysis of canine aging uncovers conserved aging pathways. GeroScience (2025). https://doi.org/10.1007/s11357-025-02029-2
[IMG: Journal of Veterinary Internal Medicine]
May 31, 2025Immunosenescence and Inflammaging in Dogs and Cats: A Narrative ReviewMcKenzie, B.A. (2025), Immunosenescence and Inflammaging in Dogs and Cats: A Narrative Review. J Vet Intern Med, 39: e70159. https://doi.org/10.1111/jvim.70159
[IMG: Scientific Reports]
April 25, 2025Translational immune and metabolic markers of aging in dogsMcMahon, J.E., Graves, J.L., Tovar, A.P. et al. Translational immune and metabolic markers of aging in dogs. Sci Rep 15, 14460 (2025). https://doi.org/10.1038/s41598-025-99349-2
[IMG: Scientific Reports]
February 13, 2025Changes in insulin, adiponectin and lipid concentrations with age are associated with frailty and reduced quality of life in dogsMcKenzie, B., Peloquin, M., Graves, J.L. et al. Changes in insulin, adiponectin and lipid concentrations with age are associated with frailty and reduced quality of life in dogs. Sci Rep 15, 5380 (2025).
[IMG: AVMA (American Veterinary Medical Association)]
April 2024Feeding dogs a high-fat diet induces metabolic changes similar to natural aging, including dyslipidemia, hyperinsulinemia, and peripheral insulin resistanceMcKenzie B, Peloquin M, Tovar A, Graves JL, Ratcliff E, Tucker K, Vo K, Greenwood K, Halioua-Haubold CL, Juarez-Salinas D. Feeding dogs a high-fat diet induces metabolic changes similar to natural aging, including dyslipidemia, hyperinsulinemia, and peripheral insulin resistance. AVMA. 2024 Apr 15. (published online ahead of print 2024).
[IMG: GeroScience]
February 2023Evaluating instruments for assessing healthspan: a multi-center cross-sectional study on health-related quality of life (HRQL) and frailty in the companion dogChen FL, Ullal TV, Graves JL, Ratcliff ER, Naka A, McKenzie B, Carttar TA, Super KM, Austriaco J, Weber SY, Vaughn J, LaCroix-Fralish ML. Evaluating instruments for assessing healthspan: a multi-center cross-sectional study on health-related quality of life (HRQL) and frailty in the companion dog. GeroScience. 2023 Feb 13.
[IMG: AVMA (American Veterinary Medical Association)]
June 2022The phenotype of aging in the dog: how aging impacts the health and well-being of dogs and their caregiversMcKenzie BA, Chen FL, LaCroix-Fralish ML. The phenotype of aging in the dog: how aging impacts the health and well-being of dogs and their caregivers. AVMA. 2022 Jun 1;260(9):963-70.
[IMG: AVMA (American Veterinary Medical Association)]
June 2022Comparative veterinary geroscience: mechanism of molecular, cellular, and tissue aging in humans, laboratory animal models, and companion dogs and catsMcKenzie BA. Comparative veterinary geroscience: mechanism of molecular, cellular, and tissue aging in humans, laboratory animal models, and companion dogs and cats. AJVR. 2022 Jun 1;83(6).
[IMG: Frontiers]
April 2022Canine Geriatric Syndrome: A Framework for Advancing Research in Veterinary GeroscienceMcKenzie BA, Chen FL, Gruen ME, Olby NJ. Canine Geriatric Syndrome: A Framework for Advancing Research in Veterinary Geroscience. Front. Vet. Sci. 2022 April 21;9:853743.
[IMG: Frontiers]
September 2021Advancing genetic selection and behavioral genomics of working dogs through collaborative scienceChen FL, Zimmermann M, Hekman JP, Lord KA, Logan B, Russenberger J, et al. Advancing Genetic Selection and Behavioral Genomics of Working Dogs Through Collaborative Science. Front. Vet. Sci. 2021 Sept 6;8:662429.Meet our vet teamOur team of veterinary professionals brings the clinical expertise and perspective of vets, vets techs, and pet parents to all aspects of research and product development at Loyal. We work tirelessly to honor the needs of other professionals in the field.
[IMG: Dr. Ellen Ratcliff]
VP, Clinical and Veterinary MedicineDr. Ellen RatcliffDVM
[IMG: Dr. Brennen McKenzie]
Director, Veterinary MedicineDr. Brennen McKenzieMA, MSc, VMD
[IMG: Dr. Mary Harrison]
Clinical Development DirectorDr. Mary HarrisonMA, VetMB, MRCVS
[IMG: Dr. Brie Dichter]
Clinical Development ManagerDr. Brie DichterDVM
[IMG: Dr. Maria Botinas]
Clinical Development ManagerDr. Maria BotinasDVMSay hello at these eventsVMX 2026January 17-21, 2026Orlando, FLBooth 517WVC 2026February 15-18, 2026Las Vegas, NVBooth 1832Reach out to our teamvets@loyal.comQ&AWhat are the potential benefits of your drugs?The goal for all our programs is to develop FDA-approved drugs that extend healthy lifespan in dogs. By targeting specific pathways that lead to metabolic dysfunction, we believe we can delay age-associated disease and disability and give companion dogs substantially more time with good health, physical function, and quality of life. The STAY study and our other ambitious clinical trials will provide much more detail about the impacts of our drugs on health and lifespan. What safety data do you have for your drugs?In December 2025, LOY-002 completed its Target Animal Safety (TAS) package, the second of three major technical sections required for FDA conditional approval. The submission included a standard safety study as well as additional field safety data from 400 dogs in the STAY study. We’ll be able to share more data as we get closer to launch.For LOY-001 and LOY-003, we will submit full safety data as part of our application for expanded conditional approval (XCA). We’ll be able to disclose this data as we get closer to launching each product. What are the active pharmaceutical ingredients in your drugs?Because our products are still in development, the drugs and their exact mechanisms of action necessarily remain confidential. We’ll release these details — along with safety and efficacy data — as we get closer to launching each product.Do your drugs treat specific cancers or other age-related diseases?Our goal is to develop medications that preserve health and broadly delay or prevent age-associated disease, rather than focusing on treating specific diseases after they have already developed.What about younger or smaller dogs?We expect to support the following populations with our drugs:For LOY-002, dogs 10 years and older and between 14 and 179 poundsFor LOY-001 and LOY-003, dogs 7 years and older and at least 40 poundsClinical studies are designed to measure effectiveness among a target population, and for our lifespan extension drugs this means choosing a population that’s most likely to benefit over the duration of the study. If approved, our drugs will be labeled for use in the same populations studied in the clinical efficacy trials.Our goal is to help as many dogs as possible, and we hope to pursue additional research to expand access to a broader population in the future.Do dogs need to be healthy when taking your drugs?We expect dogs with many pre-existing conditions will be able to take our drugs and benefit from them, but any specific guidelines will be based on the results of our clinical and safety studies.How does LOY-002 work and what are the benefits?LOY-00

Skip to main contentOne step closer to a longevity drug: LOY-002 hits key FDA milestone. Read more →Products in developmentOur products aim to extend lifespan and quality of life by reducing incidence or severity of age-related diseases. We’re developing drugs in two categories:For senior dogsFor large and giant dogsDexterAge 13Pipeline overviewPreclinical StudiesPilot studyMajor technical sectionsFDA conditional approval*LOY-002✓✓✓✓LOY-001✓✓✓LOY-003✓*FDA approval not guaranteedLOY-002*FDA approvalnot guaranteedExtending lifespan by improving metabolic health inSenior dogsExtending lifespan by improving metabolic health inSenior dogsLOY-002Dosage formDaily pillChewyAge 10AboutWe’re developing LOY-002 to support healthy aging in senior dogs of nearly every size. The product is meant to target metabolic dysfunction, which may extend the number of healthy years your dog lives and support their quality of life as they age.✓✓✓✓Preclinical studiesPilot studyMajor technical sectionsFDA conditional approval(Not guaranteed)SebastianAge 11The STAY study is the largest clinical trial in veterinary medicineThis study is gathering data on the drug’s effectiveness in dogs within real-world clinical settings to support our application for FDA approval.Learn about the STAY studyAbbyAge 13LOY-001LOY-003*FDA approvalnot guaranteedLonger, healthier lives forLarge andgiant dogsLonger, healthier lives forLarge andgiant dogsLOY-001LOY-003Dosage formInjectable or daily pillAkilaAge 7AboutLarge and giant breed dogs can have as little as half the lifespan of smaller dogs. LOY-001 and LOY-003 target the biological mechanisms thought to cause this lifespan disparity.✓✓✓Preclinical studiesPilot studyMajor technical sectionsFDA conditional approval(Not guaranteed)✓Preclinical studiesPilot studyMajor technical sectionsFDA conditional approval(Not guaranteed)KirbyAge 5BodeAge 6Two unique formulationsLOY-001For dogs 7 years and older, weighing at least 40 lb, a veterinarian-administered long-acting product given a few times a yearLOY-003For dogs 5 years and older, weighing at least 60 lb, a daily pill, prescribed by your veterinarian

Skip to main contentOne step closer to a longevity drug: LOY-002 hits key FDA milestone. Read more →
[IMG: Harper the smiling dog]
HarperAge 11
[H1] Earn CE credit with the Loyal Learning Hub
The Loyal Learning Hub is an online education platform for veterinary professionals, built to help teams easily earn CE and apply canine aging science with confidence.Get started
[H3] Evidence-based CE in canine aging
RACE-approved courses taught by the experts shaping the field.01
[H3] CE on your schedule
On-demand learning in 15 minutes or a full hour—whenever you're ready.02
[H3] Built for every team member
Courses designed for DVMs, technicians, and the entire veterinary team.03
[H2] Our courses
[IMG: Understanding aging in dogs - From principles to practice]
[H4] Understanding aging in dogs - From principles to practice
Presented by Dr. Brennen McKenzie, Dr. Lisa Lippman, and Dr. Monica TarantinoCE Credit: 1 hour55m 24s
[IMG: Dog longevity 101: Aging fundamentals that every vet should know]
[H4] Dog longevity 101: Aging fundamentals that every vet should know
Presented by Dr. Brennen McKenzieCE Credit: 1 hour45m 52s
[IMG: Dog longevity 201: Improving senior dog care by applying what we know about aging]
[H4] Dog longevity 201: Improving senior dog care by applying what we know about aging
Presented by Dr. Brennen McKenzieCE Credit: 1 hour53m 22s
[IMG: Dog longevity 301: The ultimate deep dive into metabolic health, clinical lab monitoring, and extending healthy lifespan]
[H4] Dog longevity 301: The ultimate deep dive into metabolic health, clinical lab monitoring, and extending healthy lifespan
Presented by Dr. Brennen McKenzieCE Credit: 1 hour50m 02s
[IMG: New therapies in development for canine lifespan]
[H4] New therapies in development for canine lifespan
Presented by Dr. Ellen RatcliffCE Credit: 1 hour48m 34s
[IMG: A new look at old labs: Familiar lab values as potential indicators of unhealthy aging]
[H4] A new look at old labs: Familiar lab values as potential indicators of unhealthy aging
Presented by Dr. Brennen McKenzieCE Credit: 1 hour42m 52s
[IMG: Crash course: Can we influence aging? Learn the fundamentals of aging in dogs]
[H4] Crash course: Can we influence aging? Learn the fundamentals of aging in dogs
Presented by Dr. Brennen McKenzieCE Credit: 0.25 hours16m 24s
[IMG: Looking under the hood: How metabolic dysfunction impairs health in aging dogs]
[H4] Looking under the hood: How metabolic dysfunction impairs health in aging dogs
Presented by Dr. Brennen McKenzieCE Credit: 1 hour39m 36s
[IMG: Understanding aging in dogs - From principles to practice]
[H4] Understanding aging in dogs - From principles to practice
Presented by Dr. Brennen McKenzie, Dr. Lisa Lippman, and Dr. Monica TarantinoCE Credit: 1 hour55m 24s
[IMG: Dog longevity 101: Aging fundamentals that every vet should know]
[H4] Dog longevity 101: Aging fundamentals that every vet should know
Presented by Dr. Brennen McKenzieCE Credit: 1 hour45m 52s
[IMG: Dog longevity 101: Aging fundamentals that every vet should know]
[H4] Dog longevity 101: Aging fundamentals that every vet should know
Presented by Dr. Brennen McKenzieCE Credit: 1 hour45m 52s
[IMG: Dog longevity 201: Improving senior dog care by applying what we know about aging]
[H4] Dog longevity 201: Improving senior dog care by applying what we know about aging
Presented by Dr. Brennen McKenzieCE Credit: 1 hour53m 22s
[IMG: Dog longevity 301: The ultimate deep dive into metabolic health, clinical lab monitoring, and extending healthy lifespan]
[H4] Dog longevity 301: The ultimate deep dive into metabolic health, clinical lab monitoring, and extending healthy lifespan
Presented by Dr. Brennen McKenzieCE Credit: 1 hour50m 02s
[IMG: New therapies in development for canine lifespan]
[H4] New therapies in development for canine lifespan
Presented by Dr. Ellen RatcliffCE Credit: 1 hour48m 34s
[IMG: A new look at old labs: Familiar lab values as potential indicators of unhealthy aging]
[H4] A new look at old labs: Familiar lab values as potential indicators of unhealthy aging
Presented by Dr. Brennen McKenzieCE Credit: 1 hour42m 52s
[IMG: Crash course: Can we influence aging? Learn the fundamentals of aging in dogs]
[H4] Crash course: Can we influence aging? Learn the fundamentals of aging in dogs
Presented by Dr. Brennen McKenzieCE Credit: 0.25 hours16m 24s
[IMG: Looking under the hood: How metabolic dysfunction impairs health in aging dogs]
[H4] Looking under the hood: How metabolic dysfunction impairs health in aging dogs
Presented by Dr. Brennen McKenzieCE Credit: 1 hour39m 36s
[IMG: Understanding aging in dogs - From principles to practice]
[H4] Understanding aging in dogs - From principles to practice
Presented by Dr. Brennen McKenzie, Dr. Lisa Lippman, and Dr. Monica TarantinoCE Credit: 1 hour55m 24s
[H2] Meet our expert instructors
Our instructors are veterinarians, clinicians, and researchers.
[IMG: Dr. Monica Tarantino]
[H4] Dr. Monica Tarantino
Co-founder of Senior & Geriatric Dog SocietyDVMMBA
[IMG: Dr. Lisa Lippman]
[H4] Dr. Lisa Lippman
Director of Virtual Medicine @ Bond VetDVM
[IMG: Dr. Ellen Ratcliff]
[H4] Dr. Ellen Ratcliff
VP, Clinical and Veterinary MedicineDVM
[IMG: Dr. Brennen McKenzie]
[H4] Dr. Brennen McKenzie
Director of Veterinary Medicine @ LoyalMAMScVMD
[IMG: Dr. Monica Tarantino]
[H4] Dr. Monica Tarantino
Co-founder of Senior & Geriatric Dog SocietyDVMMBA
[IMG: Dr. Lisa Lippman]
[H4] Dr. Lisa Lippman
Director of Virtual Medicine @ Bond VetDVM
[IMG: Dr. Lisa Lippman]
[H4] Dr. Lisa Lippman
Director of Virtual Medicine @ Bond VetDVM
[IMG: Dr. Ellen Ratcliff]
[H4] Dr. Ellen Ratcliff
VP, Clinical and Veterinary MedicineDVM
[IMG: Dr. Brennen McKenzie]
[H4] Dr. Brennen McKenzie
Director of Veterinary Medicine @ LoyalMAMScVMD
[IMG: Dr. Monica Tarantino]
[H4] Dr. Monica Tarantino
Co-founder of Senior & Geriatric Dog SocietyDVMMBALoyal for vetsExplore what our longevity therapies will mean for your patients and your practice.Learn more
[IMG: Veterinarian with dog]